A Phase 1 Dose Escalation Study of ARQ 197 Given Twice Daily Continuously in Adult Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2012
At a glance
- Drugs Tivantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Jul 2012 Actual patient number changed from 46 to 51 as reported by ClinicalTrials.gov.
- 17 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 01 Jun 2009 Status changed from recruiting to completed. Final results in were presented at ASCO.